
Before he built companies, Gary Glick built a life in chemistry. From Michigan classrooms to Scorpion and Odyssey, his career turns on a recurring question: who should be in the room when the next idea begins?

He helped give immuno-oncology a working language, rebuilt an oncology operation after its cupboard was cleared, and turned a young biotech into a clinical-stage company. Now Axel Hoos is starting again.

He took the name from the brightest star in the Scorpius constellation. Now Adam Friedman is betting a Boston biotech, and up to $1.9 billion in deals, on drugging the targets everyone else called impossible.